1,061
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

An analysis of the survival impact of dexmedetomidine in children undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

, , , , , ORCID Icon, , , & show all
Pages 435-440 | Received 09 Jun 2018, Accepted 25 Jul 2018, Published online: 10 Oct 2018

References

  • Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs. 2000;59:263–268.
  • Yuen VM. Dexmedetomidine: perioperative applications in children. Paediatr Anaesth. 2010;20:256–264.
  • Gorges M, West N, Deyell R, et al. Dexmedetomidine and hydromorphone: a novel pain management strategy for the oncology ward setting during anti-GD2 immunotherapy for high-risk neuroblastoma in children. Pediatr Blood Cancer. 2015;62:29–34.
  • Sadhasivam S, Boat A, Mahmoud M. Comparison of patient-controlled analgesia with and without dexmedetomidine following spine surgery in children. J Clin Anesth. 2009;21:493–501.
  • Divatia JV, Ambulkar R. Anesthesia and cancer recurrence: what is the evidence?. J Anaesthesiol Clin Pharmacol. 2014;30:147–150.
  • Horowitz M, Neeman E, Sharon E, et al. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat Rev Clin Oncol. 2015;12:213–226.
  • Kurosawa S. Anesthesia in patients with cancer disorders. Curr Opin Anaesthesiol. 2012;25:376–384.
  • Lavon H, Matzner P, Benbenishty A, et al. Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers. Br J Anaesth. 2018;120:188–196.
  • Bruzzone A, Pinero CP, Castillo LF, et al. Alpha2-adrenoceptor action on cell proliferation and mammary tumour growth in mice. Br J Pharmacol. 2008;155:494–504.
  • Xia M, Ji NN, Duan ML, et al. Dexmedetomidine regulate the malignancy of breast cancer cells by activating alpha2-adrenoceptor/ERK signaling pathway. Eur Rev Med Pharmacol Sci. 2016;20:3500–3506.
  • Szpunar MJ, Burke KA, Dawes RP, et al. The antidepressant desipramine and alpha2-adrenergic receptor activation promote breast tumor progression in association with altered collagen structure. Cancer Prev Res (Phila). 2013;6:1262–1272.
  • Cata JP, Singh V, Lee BM, et al. Intraoperative use of dexmedetomidine is associated with decreased overall survival after lung cancer surgery. J Anaesthesiol Clin Pharmacol. 2017;33:317–323.
  • Sugarbaker P. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: progress toward a new standard of care. Cancer Treatment Rev. 2016;48:42–49.
  • Hayes-Jordan A, Green H, Lin H, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for children, adolescents, and young adults: the first 50 cases. Ann Sur Oncol. 2015;22:1726–1732.
  • Schoenfeld D. Chi-squared goodness-of-fit tests for the proportional hazards regression model. Biometrika. 1980;67:145–153.
  • Cai QH, Tang Y, Fan SH, et al. In vivo effects of dexmedetomidine on immune function and tumor growth in rats with ovarian cancer through inhibiting the p38MAPK/NF-kappaB signaling pathway. Biomed Pharmacother. 2017;95:1830–1837.
  • Bulbul A, Fahy BN, Xiu J, et al. Desmoplastic small round blue cell tumor: a review of treatment and potential therapeutic genomic alterations. Sarcoma. 2017;2017:1278268.
  • Hettmer S, Li Z, Billin AN, et al. Rhabdomyosarcoma: current challenges and their implications for developing therapies. Cold Spring Harb Perspect Med. 2014;4:a025650.
  • Oyeniyi J, Wu J, Liu D, et al. Treatment of carcinomatosis using cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in adolescents and young adults. Am J Surg. 2015;209:610–615.
  • Gerlach AT, Murphy CV, Dasta JF. An updated focused review of dexmedetomidine in adults. Ann Pharmacother. 2009;43:2064–2074.
  • Hayes-Jordan A, Green HL, Lin H, et al. Complete cytoreduction and HIPEC improves survival in desmoplastic small round cell tumor. Ann Surg Oncol. 2014;21:220–224.
  • Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol. 2007;14:128–133.